The MDS-UPDRS and CDR-SB cannot cleanly separate symptomatic relief from disease modification, and EVOKE showed the converse failure mode, biomarker movement without clinical benefit, so future trials should anchor on objective measures such as dopamine-transporter SPECT, neurofilament light chain, and tau, amyloid, and neuroinflammation PET
Lead series optimization Our goal was to enhance interactions of the small-molecule agonists with the GLP-1R through lowering the energy barrier to achieve the receptor-bound agonist conformation, and by adjusting polar substituents, with minimal increases in molecular weight
Examples frequently discussed within longevity and wellness settings include peptides such as BPC-157, CJC-1295 and Ipamorelin, as well as GLP-1-related therapies, although clinical evidence, regulatory status and research depth vary significantly between compounds and treatment categories
Paul Hargrave (University of Florida, Gainesville)